Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma*

The Clinicopathological and Gene Expression Profile (CP‐GEP) model was developed to accurately identify patients with T1–T3 primary cutaneous melanoma at low risk for nodal metastasis.

[1]  C. Ramana,et al.  Model Combining Tumor Molecular and Clinicopathologic Risk Factors Predicts Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma , 2020, JCO precision oncology.

[2]  D. Byrd,et al.  Age-Specific Incidence of Melanoma in the United States. , 2019, JAMA dermatology.

[3]  G. Botti,et al.  New paradigm for stage III melanoma: from surgery to adjuvant treatment , 2019, Journal of Translational Medicine.

[4]  Lesly A. Dossett,et al.  Economic impact of the 31-gene expression profile test in the Medicare-eligible population with cutaneous melanoma. , 2019, Journal of Clinical Oncology.

[5]  S. Swetter,et al.  Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[6]  P. V. van Diest,et al.  Trends in Sentinel Lymph Node Biopsy Enactment for Cutaneous Melanoma , 2019, Annals of Surgical Oncology.

[7]  J. Wayne,et al.  Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling. , 2019, Future oncology.

[8]  A. Gavin,et al.  Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. , 2018, European journal of cancer.

[9]  T. Miner,et al.  Suboptimal Compliance With National Comprehensive Cancer Network Melanoma Guidelines: Who Is at Risk? , 2018, American journal of clinical oncology.

[10]  M. Shabahang,et al.  Hospital-Based Study of Compliance with NCCN Guidelines and Predictive Factors of Sentinel Lymph Node Biopsy in the Setting of Thin Melanoma Using the National Cancer Database , 2018, The American surgeon.

[11]  H. Soyer,et al.  Generational shift in melanoma incidence and mortality in Queensland, Australia, 1995–2014 , 2018, International journal of cancer.

[12]  D. Schadendorf,et al.  Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma , 2018, The New England journal of medicine.

[13]  Jeffrey E Gershenwald,et al.  Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.

[14]  P. Ascierto,et al.  Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma , 2017, The New England journal of medicine.

[15]  A. Hauschild,et al.  Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma , 2017, The New England journal of medicine.

[16]  A. Gesierich,et al.  Completion Dissection or Observation for Sentinel‐Node Metastasis in Melanoma , 2017, The New England journal of medicine.

[17]  D. Moreno-Ramírez,et al.  Making decisions on sentinel lymph node biopsy for malignant melanoma: prioritization of determinants using a decision tree , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[18]  M. Louwman,et al.  Implementation of the 7th edition AJCC staging system: Effects on staging and survival for pT1 melanoma. A Dutch population based study , 2017, International journal of cancer.

[19]  A. Carbone,et al.  Complications of sentinel lymph node biopsy for melanoma - A systematic review of the literature. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[20]  P. Rutkowski,et al.  Effects of time interval between primary melanoma excision and sentinel node biopsy on positivity rate and survival. , 2016, European journal of cancer.

[21]  A. Benson,et al.  Adjusted Hospital Sentinel Lymph Node Positivity Rates in Melanoma: A Novel Potential Measure of Quality , 2016, Annals of surgery.

[22]  G. Collins,et al.  Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement , 2015, Annals of Internal Medicine.

[23]  J. Gershenwald,et al.  Clinical value of the sentinel-node biopsy in primary cutaneous melanoma. , 2014, The New England journal of medicine.

[24]  R. Elashoff,et al.  Final trial report of sentinel-node biopsy versus nodal observation in melanoma. , 2014, The New England journal of medicine.

[25]  V. Sondak,et al.  Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  K. Chalkidou.  About the National Institute for Health and Care Excellence - NICE. , 2013, Acta medica portuguesa.

[27]  M. Kashani-Sabet,et al.  The effect of delay time between primary melanoma biopsy and sentinel lymph node dissection on sentinel node status, recurrence, and survival , 2012, Melanoma research.

[28]  Cornelis Verhoef,et al.  EORTC Melanoma Group sentinel node protocol identifies high rate of submicrometastases according to Rotterdam Criteria. , 2010, European journal of cancer.

[29]  R. Rosenfeld,et al.  Cases , 2010, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[30]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Mihm,et al.  EANM-EORTC general recommendations for sentinel node diagnostics in melanoma , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[32]  C. Balch,et al.  Health care system and socioeconomic factors associated with variance in use of sentinel lymph node biopsy for melanoma in the United States. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  L. French,et al.  The influence of sentinel lymph node tumour burden on additional lymph node involvement and disease-free survival in cutaneous melanoma – a retrospective analysis of 392 cases , 2008, British Journal of Cancer.

[34]  M. Casparie,et al.  Pathology Databanking and Biobanking in The Netherlands, a Central Role for PALGA, the Nationwide Histopathology and Cytopathology Data Network and Archive , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[35]  R. Elashoff,et al.  Sentinel-node biopsy or nodal observation in melanoma. , 2006, The New England journal of medicine.

[36]  A. Eggermont,et al.  High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma. , 2006, European journal of cancer.

[37]  Xianglin L. Du,et al.  Population-based assessment of surgical treatment trends for patients with melanoma in the era of sentinel lymph node biopsy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  N Cascinelli,et al.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  D L Morton,et al.  Technical details of intraoperative lymphatic mapping for early stage melanoma. , 1992, Archives of surgery.

[40]  A. Hauschild,et al.  Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012. , 2012, European journal of cancer.

[41]  Donald E. Henson,et al.  Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989 .